Harpoon Therapeutics, Inc. (HARP)
| Market Cap | 427.46M |
| Revenue (ttm) | 37.34M |
| Net Income (ttm) | -30.50M |
| Shares Out | 37.60M |
| EPS (ttm) | -8.76 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 105,226 |
| Open | 11.46 |
| Previous Close | 11.44 |
| Day's Range | 11.05 - 11.70 |
| 52-Week Range | 3.11 - 15.19 |
| Beta | 2.08 |
| Analysts | Strong Buy |
| Price Target | 21.67 (+90.59%) |
| Earnings Date | Nov 9, 2023 |
About HARP
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I c... [Read more]
Financial Performance
In 2022, HARP's revenue was $31.92 million, an increase of 34.92% compared to the previous year's $23.65 million. Losses were -$67.73 million, -41.97% less than in 2021.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for HARP stock is "Strong Buy." The 12-month stock price forecast is $21.67, which is an increase of 90.59% from the latest price.
News
Harpoon Therapeutics Strengthens Leadership Team
James Bucher, J.D. joins as Chief Legal Officer Wendy Chang promoted to Chief People Officer SOUTH SAN FRANCISCO, Calif.
Harpoon Therapeutics Abstract for HPN328 Accepted for Rapid Oral Presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium
SOUTH SAN FRANCISCO, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced abstr...
Harpoon Therapeutics Presents HPN217 Phase 1 Clinical Data in Relapsed/Refractory Multiple Myeloma (RRMM) at ASH 2023 and Announces Selection of Recommended Phase 2 Dose (RP2D)
• HPN217 was well tolerated and demonstrated robust and durable clinical activity at doses ranging from 2.15 to 24 mg in heavily pre-treated patients, including patients with prior exposure to BCMA-t...
Harpoon Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
October 2023 financing funds late-stage clinical trials of HPN328 in multiple tumor types Positive interim results from Phase 1/2 trial of T cell engager HPN328 in patients with small cell lung cancer...
Harpoon Therapeutics Abstract for HPN217 Accepted for Presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced abstr...
Harpoon Therapeutics Announces Up to $150 Million Private Placement
SOUTH SAN FRANCISCO, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP) (the “Company”), a clinical-stage immunotherapy company developing novel T cell engagers, today...
Harpoon Therapeutics Announces Updated Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced the u...
Harpoon Therapeutics to Host Webcast Reviewing HPN328 Interim Data Presented at ESMO Congress 2023 on October 23, 2023
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that ...
Harpoon Therapeutics to Present Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023
SOUTH SAN FRANCISCO, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that ...
Harpoon Therapeutics Presents HPN217 Interim Phase 1 Data at the IMS Annual Meeting
Target dose of 12 mg demonstrates robust early activity and manageable tolerability profile: – 63% ORR, 16% cytokine release syndrome (CRS), No ICANS –
Harpoon Therapeutics Announces First Patients with Small Cell Lung Cancer Dosed in HPN328 Combination Cohort
SOUTH SAN FRANCISCO, Calif., Sept. 15, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced do...
Harpoon Therapeutics Provides an Update on the HPN217 Development and Option Agreement with AbbVie
SOUTH SAN FRANCISCO, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, announced today th...
Harpoon Therapeutics Abstract for HPN217 Accepted for Poster Presentation at the 20th International Myeloma Society Annual Meeting
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced ab...
Harpoon Therapeutics to Host KOL Event in Person and via Webcast on September 15, 2023
KOLs to provide insight and discussion of HPN328 targeting SCLC, NEPC and other neuroendocrine tumors Abstract with HPN328 interim data accepted for poster presentation at the European Society for Med...
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences in September
SOUTH SAN FRANCISCO, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that...
Harpoon Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Abstracts for HPN217 and HPN328 accepted for presentations at the International Myeloma Society (IMS) Annual Meeting and the European Society for Medical Oncology (ESMO) in the fall
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences in August
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that ...
Harpoon Therapeutics Appoints Haibo Wang as Senior Vice President of Business Development
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced the...
Replicate Bioscience Appoints Rachael Lester as Chief Business Officer
Biopharma executive with more than 20 years of global corporate, business development, and commercial strategy experience to join Replicate leadership team SAN DIEGO , July 10, 2023 /PRNewswire/ -- Re...
Harpoon Therapeutics Announces Completion of Planned Patient Enrollment in Phase 1 Study of HPN217 in Relapsed/Refractory Multiple Myeloma
SOUTH SAN FRANCISCO, Calif., June 27, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced the...
Harpoon Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
Enrollment for HPN217 (BCMA) and HPN328 (DLL3) remain on track, with data updates and selection of recommended Phase 2 doses for both ongoing clinical programs planned in 2023
Harpoon Therapeutics Presents Preclinical Results for Novel T Cell Engagers HPN217 and HPN328 at AACR 2023
SOUTH SAN FRANCISCO, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today presented pr...
Harpoon Therapeutics Presents Data for New ProTriTAC™ Development Candidates in TROP2- and ITGB6-expressing Solid Tumors at AACR 2023
Results support further investigation of two new ProTriTAC™ protease-activated T cell engager development candidates, with demonstrated therapeutic potential in a broad range of TROP2- and integrin-be...
Harpoon Therapeutics to Participate in the Canaccord Horizons in Oncology Conference
SOUTH SAN FRANCISCO, Calif., April 10, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced th...
Harpoon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
HPN217 (BCMA) and HPN328 (DLL3) enrollment on track, with data updates and selection of recommended Phase 2 doses for both active clinical programs planned in 2023